Study of sivelestat for neuromyelitis optica spectrum disorder
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a drug called sivelestat to see if it can help people who are currently having a relapse of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. The study aims to find out if the drug is safe and if it reduces symptoms during a relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with NMOSD and are positive for AQP4 antibodies.
- You are currently having a relapse that started within the last 14 days.
- The relapse affects your optic nerve (causing eye pain or vision loss) or your spinal cord (causing weakness, numbness, or bladder problems).
- Your symptoms worsened by at least one point on a standard disability scale.
- You are 18 years or older.
- You are able to give written informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at treatments for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a sudden attack affecting their vision or spinal cord. It aims to find out which treatments work best in everyday practice.
This trial tests an antibody treatment for people having a neuromyelitis optica (NMO) relapse. It may reduce nerve damage from inflammation during an acute attack.
This trial studies inebilizumab to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are having an acute attack. It aims to reduce ongoing nerve damage and disability after a recent flare, alongside standard steroid treatment.
This study looks at how well satralizumab works in people with NMOSD (a rare disorder that affects the nerves in your eyes and spine). It is for people who have had recent flare-ups and test positive for a specific antibody (AQP4). You will receive satralizumab and be followed for at least one year to see if your disease stays under control.
This trial tests a new treatment called NouvSoma001 for neuromyelitis optica spectrum disorder (NMOSD), a condition where the immune system attacks the optic nerves and spinal cord. It looks at whether the drug is safe and helps people who have had a recent attack with severe pain, trouble walking, or bladder/bowel problems.
This trial tests a new drug called IMC-002 for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4+). It aims to see if IMC-002 is safe and effective at preventing attacks.
Hear when a new Neuromyelitis Optica Spectrum Disorder Attack trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.